Global Business: Winners and Losers of the Pandemic Crisis Are on the Increase

Although this year’s economic growth has been fast so far as expected, another wave of the pandemic, especially as a result of the Delta variant, may have negative effects. There are some signals of such development: the US service sector saw a slowdown in June and the growth in Chinese plants was at a four-month low. Oil prices have also experienced a decline as a response to the rapid spread of Delta.

 

Predominantly the travel industry is among the sectors that may suffer new hits after a short recovery. This is explicitly confirmed, for example, by the UN stating that this year, the global economy may see a production decline of nearly USD 2.4 trillion as reported in 2020, primarily as a consequence of the pandemic impact on travelling and its related industries.

 

On the other hand, industries that primarily profit from the repeated fall in the epidemic data, and the resulting reassessment of originally optimistic expectations relating to the speed of economic recovery, may continue to include pharmacy, biotechnologies, and medical supplies and services.

 

According to a study of APME FX, the companies that deserve a long-term attention in the above-mentioned sectors comprise namely BioNTech (pharmacy), Regeneron (biotechnologies), Medtronic (medical technologies and equipment) and UnitedHealth Group (insurance). The companies came with effective vaccines (BioNTech) or drugs (Regeneron) against SARS-CoV-2 in record time, which was reflected in their sales significantly. This was also driving the market value of those companies, which was the case of the medical giant Medtronic and Moderna that made a great achievement in mid-July when it was added to the S&P 500. The company’s stocks grew several times over the last year.

 

Out of the largest health insurance companies, significantly positive data since the start of the pandemic has been reported by UnitedHealth Group. For more details on the performance of the companies selected by APME FX, refer to the World Health Care Investments 2021 study here.

Peter Svoreň, APME FX

Disclaimer:

The material herein is considered as marketing communication under the relevant laws and regulations, and as such is not a subject to any prohibition on dealing ahead of the dissemination of investment research. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and should not be construed as containing investment advice, or an investment recommendation, or an offer of or solicitation for any transactions in financial instruments. The published content is intended for educational/informational purposes only. It does not take into account readers’ financial situation, personal experience or investment objectives. APME FX Trading Europe Ltd makes no representation that the information provided is accurate, current or complete; and therefore, assumes no liability for any losses arising from investments based on the supplied content. The past performance is not a guarantee of future results.

Blog

Four years since Brexit: Despite the dark scenarios, no disaster happens

At the end of this January, four years have passed since Great Britain officially left the European Union. Although remainers have warned that the UK will pay a price to leave, there is so far no sign t...

Blog

European central bank will likely decrease the rates soon. Inflation has decelerated substantially

The European Central Bank has most likely definitively ended its cycle of raising interest rates, and the first decrease will probably come already during the spring period. Not only many experts think...

Blog

No Cheers Over the Hesitant Economic Recovery of the EU

The economic performance of the European Union will practically stagnate this year. For next year, key institutions expect a slight acceleration of GDP growth, with inflation currently falling to a leve...

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 86,61% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please read the Risk Disclosure and Warning Notice